

Phase 1b Trial Update: Evaluating Tegoprubart For The Prevention of Rejection In Patients Undergoing Kidney Transplantation

November 2, 2023



Forward-Looking Statements

This presentation contains forward-looking statements that involves substantial risks and uncertainties. Any statements about the company's future expectations, plans and prospects, including statements about its strategy, future operations, development of its product candidates, and other statements containing the words "believes," "anticipates," "plans," "expects," "estimates," "intends," "predicts," "projects," "targets," "could," "may," and similar expressions, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, although not all forward-looking statements regarding: expectations regarding the timing for the commencement and completion of product development or clinical trials; the rate and degree of market acceptance and clinical utility of the company's products; the company's commercialization, marketing and manufacturing capabilities and strategy; the company's intellectual property position and strategy; the company's ergarding expenses, future revenue, capital requirements and needs for additional financing; developments relating to the company's competitors and industry; and the impact of government laws and regulations.

Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the ability to develop commercially viable product formulations; the sufficiency of the company's cash resources; the ability to obtain necessary regulatory and ethics approvals to commence additional clinical trials; whether data from early clinical trials will be indicative of the data that will be obtained from future clinical trials; whether the results of clinical trials will warrant submission for regulatory approval of any investigational product; whether any such submission will receive approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies and, if we are able to obtain such approval for an investigational product, whether it will be successfully distributed and marketed. These risks and uncertainties, as well as other risks and uncertainties that could cause the company's actual results to differ significantly from the forward-looking statements contained herein, are discussed in our annual report on Form 10-K for the year ended December 31, 2022, and other filings with the SEC which can be found at www.sec.gov. Any forward-looking statements contained in this presentation speak only as of the date hereof and not of any are are sult of new information, future events or otherwise.

Photo: Gertrude "Trudy" Elion, inventor of azathioprine and recipient of Nobel Prize in Medicine in 1988.

Tegoprubart: Transplantation Focused Pipeline in a Product Opportunity

		DEVELOPMI			
Indications	Pre-clinical	Phase 1 / Early Human Trials	Phase 2	Phase 3	
Kidney Transplantation					 Phase 2 BESTOW and ex-US Phase 1b enrolling Sub-cutaneous formulation completed non-human primate study
Xenotransplantation					 Cardiac xenotransplantation performed at University of Maryland eGenesis & academic collaborations
Liver Transplantation					Academic collaboration
Amyotrophic Lateral Sclerosis (ALS)					 Seeking non-equity dilutive financing to advance program to Phase 3





Kidney Transplantation Immunosuppression Market Represents a Multi-Billion Dollar Commercial Opportunity

Large Patient Population





People living with a functioning kidney transplant

90,000+ Americans on transplant waiting list 5,000 Americans per year die waiting for a kidney transplant

~15% of U.S. adults on waitlist are waiting for repeat transplants



Kidney Transplants Annually 25,000+ 21,000+

Average age transplant U.S. **50 years old** Average organ only functions **10-15 years** Many patients require repeat transplants

Heavy Economic Burden

End Stage Renal Disease & Transplant

\$50+ Billion annual U.S. Medicare expenditure including Kidney Transplantation costs of \$420,000+ / transplant

Medicare covers cost of immunosuppressive transplant drugs, regardless of patient age, if patient does not have other insurance

Global organ transplant immunosuppressant market size estimated **\$5.3+ billion** Astellas reported tacrolimus global revenues ~\$1.5B in FY2022 (Prograf, first FDA approval 1994)

Early graft failure of transplanted kidneys


\$150,000+ average incremental U.S., medical costs / patient year after graft failure

Patients returning to dialysis: ▼ quality of life < 50% 5-year survival rate Re-transplants deplete an already inadequate donor organ pool



Mechanism Overview of CD40L Inflammatory Signaling

CD40/CD40L Pathway and Tegoprubart Site of Action




- Interaction of CD40 with CD40Lon immune cells mediates activation of the co-stimulatory immune pathway, controlling "cross talk" between the adaptive and innate immune systems
- Maximal activation of inflammatory system is a 3-step process requiring co-stimulatory signaling
 - Step 1: Major histocompatibility complexes (MHC) and CD3/TCR engagement
 - Step 2: CD40 and CD40L binding resulting in cell division and clonal expansion
 - **Step 3:** Pro-inflammatory response by polarized T cells expressing inflammatory chemokines and cytokines
- Blocking CD40L shifts polarization away from proinflammatory signaling to T cell anergy, apoptosis, and polarization to a Treg environment
 - Blocking CD40L thus does not generally result in lymphopenia often seen with immunosuppressive agents



Removing CNIs May Stop the Cycle of Transplantation and Subsequent CNI Related Graft Failure

CNI side effects are a leading cause of kidney graft failure over time....



....and can lead to a cycle of transplantation and graft failure

CNI Associated Kidney Damage

- Nephrotoxicity
- Hypertension
- Diabetes

Transplant

\$440,000+ avg. cost per U.S. patient

Graft Failure

\$150,000+ avg. incremental medical costs per patient post graft failure

Dialysis & Kidney Wait List

- ~15% of adults on waitlist are for repeat transplants
- ~15% to 20% mortality rate in 1st year of dialysis




Distribution of eGFRs Using Standard of Care Post Transplant: Median ~51 mL/min/1.73m2 in First Year

	No. of			eGFR Value (mL/min/1.73 m ²) at Listed Percentiles				Percentage in Listed eGFR (in mL/min/1.73 m ²) Categories						
Time Posttransplant	Centers	Patients	eGFR Values	5th	25th	50th	75th	95th	≥90	60-89	45-59	30-44	15-29	<15
Discharge	11	23,053	18,393	11	31	45	60	86	4	21	26	26	15	9
1 mo	8	22,597	12,715	21	38	50	62	85	4	25	32	27	10	2
3 mo	9	21,894	12,887	26	40	51	63	86	4	27	33	28	8	1
6 mo	9	21,212	13,272	26	40	51	62	84	3	26	35	28	7	1
1 y	12	19,989	13,671	25	39	50	61	83	3	24	34	29	9	1
2 y	10	17,449	11,298	23	38	49	62	83	3	25	32	28	11	1
Зу	11	15,103	10,221	22	37	49	61	83	3	24	31	29	12	2
4 y	10	12,806	8,520	21	37	48	61	84	3	23	31	28	12	2
5у	10	10,620	7,269	21	36	48	61	83	3	23	29	30	13	2

Abbreviations: CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate.

Kidney Allograft Function is an Early Predictor of Future Graft Failure

eGFR at 12 months is associated with subsequent death-censored graft failure



- Graft function measured using eGFR at 12 months post transplant is associated independently with subsequent graft failure
- Of multiple covariates, 12-month eGFR is the strongest predictor of graft failure



Phase 1b and Phase 2 Kidney Transplantation Studies are Running in Parallel

Up to 12 participants undergoing kidney transplantation

> Canada, UK and Australia

52-week, open label, single arm study

ATG induction therapy plus

CNI-free maintenance therapy with tegoprubart

(as a replacement for tacrolimus) as part of a maintenance immunosuppressive regimen including mycophenolate and a corticosteroid taper

Primary endpoints:

Safety & tolerability

Secondary endpoints:

- Graft function (eGFR)
- · Participant and graft survival
- Biopsy proven acute rejection (BPAR)
- · Immune cell infiltrate of graft biopsy
- Biomarker measures of kidney injury and rejection risk

Phase 2 "BESTOW"

~120 participants (60/arm) undergoing kidney transplantation

U.S. and other countries

52-week, head-to-head, superiority study

ATG induction therapy plus

CNI-free maintenance therapy with tegoprubart or tacrolimus

as part of a maintenance immunosuppressive regimen including mycophenolate and a corticosteroid taper

Primary endpoints:

- Graft function (eGFR)
- Safety & tolerability

Secondary endpoints:

- · Participant and graft survival
- Biopsy proven acute rejection (BPAR)
- · Immune cell infiltrate of graft biopsy
- Rate of new onset diabetes mellitus (NODAT)
- Biomarker measures of kidney injury and rejection risk



Phase 1b Kidney Transplantation: Demographics & Disposition

Participant	Age/Gender	Ethnicity	Donor	Underlying Disease	Days Post TxP (DS: Discontinued Study)	Status
1	60/F	White	Living	Polycystic Kidney Disease	217 (DS)	Discontinued study on day 217 due to alopecia and fatigue
2	77/F	White	Deceased	Diabetes	380	
3	62/M	White	Living	Cystic Disease	54 (DS)	Discontinued study on day 54 due to Polyomavirus viremia
4	68/M	White	Living	Diabetes	217	
5	23/F	Asian	Living	Glomerulonephritis	181	
6	44/M	White	Deceased	Polycystic Kidney Disease	154	
7	65/M	White	Living	Type 1 Diabetes	146	
8	57/F	White	Living	Diabetes	83	
9	35/M	Other	Living	Glomerulonephritis	75	
10	56/F	White	Living	Polycystic Kidney Disease	60	
11	59/M	White	Living	Diabetes	43	



Phase 1b Kidney Transplantation: Treatment Emergent Adverse Events


System Organ Class	Preferred Term	N (%)		
	Diarrhea	5 (45%)		
Gastrointestinal	Constipation	4 (36%)		
ouounina	Nausea	3 (27%)		
	Vomiting	2 (18%)		
Infections	Polyomavirus viremia	4 (36%)		
inections	Urinary tract Infection	2 (18%)		
Procedural Complication	Complications of Transplant Surgery	3 (27%)		
ricedular complication	Procedural pain	2 (18%)		
Direct and Laurahadia Contant	Leukopenia	2 (18%)		
Blood and Lymphatic System	Neutropenia	2 (18%)		
Cardiac	Tachycardia	2 (18%)		
Company	Oedema peripheral	2 (18%)		
General	Pyrexia	2 (18%)		
Metabolism	Hypoglycemia	2 (18%)		
Metabolism	Hypophosphatemia	2 (18%)		
Musculoskeletal and Connective Tissue	Back pain	2 (18%)		
Skin and Subcutaneous tissue	Alopecia	2 (18%)		
Vascular	Hypertension	2 (18%)		
vascular	Hypotension	2 (18%)		

* Occurring in 2 or more study subjects as of October 13, 2023. Of all the reported TEAEs, 7 events experienced by 3 subjects are reported as serious. These SAEs include neutropenia, acute kidney injury, T-cell rejection, Polyomavirus viremia, anterior abdominal wall collection, and hyperkalemia

- 1 participant experienced a T cell mediated rejection (Banff score 1a). The patient was treated and remains in the study
- 1 patient experienced a surgical related acute tubular necrosis on day 0 (prior to administration of study drug) which impacted their kidney function. The patient continues to be in the study
- No cases of hyperglycemia, new onset diabetes, tremor, or cytomegalovirus infection



Phase 1b Kidney Transplantation: Mean eGFR Over Time



- Aggregate mean eGFR was above 70 mL/min/1.73m2 at all reported time points after day 90
- One participant completed the 12-month study with an eGFR of 91 on day 374, and is now enrolled in a Phase 2 open-label extension study

Note: Estimated glomerular filtration rate (eGFR) as of October 19, 2023, calculated using the chronic kidney disease epidemiology collaboration (CKD-EPI) creatinine equation. N is the number of participants at that time contributing data to mean eGFR calculation.



Source: ASN, November 2, 2023.

Phase 1b Kidney Transplantation: Summary Conclusions

- Data from 11 participants demonstrates tegoprubart successfully prevented kidney transplant rejection and was generally safe and well-tolerated
- Aggregate mean eGFR was above 70 mL/min/1.73m2 at all reported time points after day 90, supporting tegoprubart's potential to better protect organ function than with regimens using calcineurin inhibitors, the current standard of care
- Eledon next plans to report updated data from the Phase 1b trial mid-2024





Eledon Pharmaceuticals

19900 MacArthur Blvd., Suite 550 Irvine, California 92612, USA info@eledon.com +1 949-238-8090

